Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ligand Pharmaceuticals Inc Market Cap
Based on ratings from 7 stock analysts, the Ligand Pharmaceuticals Inc stock price is expected to increase by 12.45% in 12 months. This is calculated by using the average 12-month stock price forecast for Ligand Pharmaceuticals Inc. The lowest target is $125 and the highest is $157. Please note analyst price targets are not guaranteed and could be missed completely.
Ligand Pharmaceuticals Inc has a total of 7 Wall St Analyst ratings. There are 7 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Ligand Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LGND.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Miehm RBC Capital | Outperform | $140 | Maintains | Nov 12, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $157 | Reiterates | Nov 8, 2024 |
| Balaji Prasad Barclays | Overweight | $150 | Maintains | Nov 8, 2024 |
| Robert Wasserman Benchmark | Buy | $135 | Maintains | Nov 8, 2024 |
| Leland Gershell Oppenheimer | Outperform | $147 | Maintains | Nov 8, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $157 | Reiterates | Oct 31, 2024 |
| Balaji Prasad Barclays | Overweight | $125 | Maintains | Oct 28, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $157 | Maintains | Oct 21, 2024 |
| Leland Gershell Oppenheimer | Outperform | $135 | Initiates | Oct 3, 2024 |
| Douglas Miehm RBC Capital | Outperform | $130 | Reiterates | Aug 12, 2024 |
| Robert Wasserman Benchmark | Buy | $110 | Maintains | Aug 12, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $144 | Reiterates | Aug 8, 2024 |
| Douglas Miehm RBC Capital | Outperform | $130 | Reiterates | Aug 7, 2024 |
| Douglas Miehm RBC Capital | Outperform | $130 | Initiates | Jul 30, 2024 |
| Matt Hewitt Craig-Hallum | Buy | $140 | Maintains | Jul 9, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $144 | Reiterates | Jul 8, 2024 |
| Robert Wasserman Benchmark | Buy | $95 | Reiterates | Jun 28, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $144 | Reiterates | Jun 27, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $144 | Reiterates | May 8, 2024 |
| Robert Wasserman Benchmark | Buy | $95 | Reiterates | Apr 12, 2024 |
When did it IPO
1992
Staff Count
58
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Todd C. Davis Ph.D.
Market Cap
$2.36B
In 2023, LGND generated $131.3M in revenue, which was a decrease of -33.09% from the previous year. This can be seen as a signal that LGND's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Sun, 24 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Ligand Pharmaceuticals is rated a "Buy" due to strong liquidity and a clean balance sheet. Q3 2024 earnings exceeded expectations, prompting raised guidance.
Why It Matters - Strong Q3 2024 earnings and raised guidance signal robust financial health for Ligand Pharmaceuticals, enhancing investor confidence and potential stock performance.
Fri, 22 Nov 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - The top five biotech stocks today share strong ratings, indicating positive investor sentiment and potential stability in the sector.
Why It Matters - Strong ratings for top biotech stocks indicate robust performance and potential growth, signaling positive investor sentiment and opportunities for gains in the sector.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand Pharmaceuticals' CEO Todd Davis and CFO Tavo Espinoza will present at the Stifel 2024 Healthcare Conference on November 19, 2024, and will host one-on-one investor meetings.
Why It Matters - Ligand Pharmaceuticals' management presentation at a key healthcare conference signals potential updates on strategy and financial performance, which could impact stock valuation and investor sentiment.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Ligand Pharmaceuticals will hold its Q3 2024 earnings conference call on November 7, 2024, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters - The upcoming Q3 2024 earnings call for Ligand Pharmaceuticals may reveal key financial performance indicators and strategic insights, influencing stock valuation and investor sentiment.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand has reported its financial results for Q3 2024 and increased its guidance for the year, indicating a positive outlook for the company's performance.
Why It Matters - Ligand's strong Q3 results and raised guidance indicate improved financial health and growth prospects, potentially boosting investor confidence and stock performance.
Fri, 01 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand Pharmaceuticals will host an Investor and Analyst Day in Boston on December 10, 2024, featuring management presentations on strategy, investment, and financial outlook.
Why It Matters - Ligand Pharmaceuticals' Investor and Analyst Day signals strategic updates and financial insights, potentially influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
